Lifileucel (Amtagvi) a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.

Safety and efficacy were evaluated in a global, multicenter, multicohort, open-label, single-arm trial in patients with unresectable or metastatic melanoma who had previously been treated with at least one systemic therapy, including a PD-1 blocking antibody, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor. 

Lifileucel was administered following a lymphodepleting regimen consisting of cyclophosphamide 60 mg/kg daily with mesna for 2 days followed by fludarabine 25 mg/m2 daily for 5 days. 

Three to 24 hours after infusion, patients received IL-2 (aldesleukin) at 600,000 IU/kg every 8 to 12 hours for up to 6 doses in order to support cell expansion in vivo. 

The median administered lifileucel dose was 21.1× 109 viable cells. 

The median number of administered IL-2 (aldesleukin) doses was 6.

The main efficacy outcome measures were objective response rate (ORR) and duration of response (DoR). 

The median time to initial response to lifileucel was 1.5 months. 

ORR was based on 73 subjects who received lifileucel within the recommended dosing range of 7.5 x109 to 72×109 viable cells. ORR was 31.5% (95% CI: 21.1, 43.4) and median DoR was not reached (NR): 4.1 months, NR).

Contains a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary, and renal impairment. 

The most common adverse reactions (≥20%) in order of decreasing frequency were chills, pyrexia, fatigue, tachycardia, diarrhea, febrile neutropenia, edema, rash hypotension, alopecia, infection, hypoxia, and dyspnea.

The recommended lifileucel dose is 7.5 x 109 to 72 x 109 viable cells.

Leave a Reply

Your email address will not be published. Required fields are marked *